Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1158/0008-5472.can-11-1227

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

..., James H. Doroshow
75
Cancer Research11.20
Volume: 71, Issue: 17, Pages: 5626 - 5634
Published: Aug 30, 2011
Abstract
A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a topoisomerase I-targeted agent, was carried out to determine maximum tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of the combination in patients with refractory solid tumors and lymphomas. Varying schedules and doses of intravenous topotecan in combination with ABT-888 (10 mg) administered orally twice a day (BID) were evaluated....
Paper Fields
Paper Details
Title
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
DOI
doi.org/10.1158/0008-5472.can-11-1227
Published Date
Aug 30, 2011
Journal
Cancer Research
Volume
71
Issue
17
Pages
5626 - 5634
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.